<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40323649</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Stoma Rate and Oncological Outcomes of Primary TaTME vs Completion TaTME in Patients With Early-Stage Rectal Cancer.</ArticleTitle><Pagination><StartPage>962</StartPage><EndPage>971</EndPage><MedlinePgn>962-971</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003794</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Local excision as a first step in the treatment of early rectal cancer has gained interest. However, in the presence of histopathological risk factors, (inter)national guidelines recommend completion total mesorectal excision. Although oncologically safe, completion total mesorectal excision is associated with an increased end colostomy rate compared to primary total mesorectal excision, especially in distal lesions. Transanal total mesorectal excision may facilitate lower anastomoses, potentially reducing end colostomy rates.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the end colostomy rate and oncological outcomes of primary transanal total mesorectal excision with local excision followed by completion transanal total mesorectal excision in patients with cT1-2N0M0 rectal cancer.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Data were prospectively collected and retrospectively analyzed.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">This study was conducted in 6 Dutch high-volume centers experienced in transanal total mesorectal excision.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">All patients with cT1-2N0M0 rectal cancer who underwent primary transanal total mesorectal excision or local excision followed by completion transanal total mesorectal excision between 2012 and 2022.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The primary outcome was end colostomy rate. Secondary outcomes included anastomotic leakage, involvement of the circumferential resection margin, specimen quality, local recurrence, distant metastases, overall survival, and disease-free survival.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 150 patients were included with a median follow-up of 32 and 23 months for primary transanal total mesorectal excision and local excision followed by completion transanal total mesorectal excision, respectively. The end colostomy rate was significantly lower in the local excision followed by completion transanal total mesorectal excision group (21%) compared to the primary transanal total mesorectal excision group (42%, p = 0.022). More anastomotic leakages occurred in the local excision followed by completion transanal total mesorectal excision group (33% vs 18%, p = 0.064). No differences were observed in circumferential resection margin involvement and specimen quality. Two-year local recurrence rates were 4% for primary transanal total mesorectal excision and 3% for local excision followed by completion transanal total mesorectal excision ( p = 0.343), whereas distant metastases occurred in 8% and 10% ( p = 0.424), respectively. There were no significant differences in 2-year overall survival (88% vs 97%, p = 0.101) and 2-year disease-free survival (82% vs 90%, p = 0.463) between groups.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The small sample size, which precluded correction for group differences, and selection bias.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study demonstrated that local excision followed by completion transanal total mesorectal excision for cT1-2N0 rectal cancer neither increased the end colostomy rate nor compromised oncological outcomes compared to primary transanal total mesorectal excision in experienced centers. See Video Abstract .</AbstractText><AbstractText Label="TASA DE ESTOMAS Y RESULTADOS ONCOLGICOS DE LA TATME PRIMARIA FRENTE A LA TATME DE COMPLEMENTO EN PACIENTES CON CNCER RECTAL EN ESTADIO TEMPRANO" NlmCategory="UNASSIGNED">ANTECEDENTES:La escisi&#xf3;n local como primer paso en el tratamiento del c&#xe1;ncer rectal en estadio temprano ha despertado inter&#xe9;s. Sin embargo, en presencia de factores de riesgo histopatol&#xf3;gicos, las directrices internacionales recomiendan la escisi&#xf3;n mesorrectal total completa. Aunque es segura desde el punto de vista oncol&#xf3;gico, la escisi&#xf3;n mesorrectal total de complemento se asocia con una mayor tasa de colostom&#xed;a terminal en comparaci&#xf3;n con la escisi&#xf3;n mesorrectal total primaria, especialmente en lesiones distales. La escisi&#xf3;n mesorrectal total transanal puede facilitar las anastomosis m&#xe1;s bajas, lo que podr&#xed;a reducir las tasas de colostom&#xed;a terminal.OBJETIVO:Comparar la tasa de colostom&#xed;a terminal y los resultados oncol&#xf3;gicos de la escisi&#xf3;n mesorrectal total transanal primaria con la escisi&#xf3;n local seguida de la escisi&#xf3;n mesorrectal total transanal de complemento en pacientes con c&#xe1;ncer rectal cT1-2N0M0.DISE&#xd1;O:Los datos se recopilaron de forma prospectiva en seis centros holandeses con gran volumen de experiencia en la escisi&#xf3;n mesorrectal total transanal y se analizaron retrospectivamente.PACIENTES:Todos los pacientes con c&#xe1;ncer rectal cT1-2N0M0 que se sometieron a una escisi&#xf3;n mesorrectal total transanal primaria o a una escisi&#xf3;n local seguida de una escisi&#xf3;n mesorrectal total transanal de complemento entre 2012 y 2022.PRINCIPALES MEDIDAS DE RESULTADO:El resultado principal fue la tasa de colostom&#xed;a terminal. Los resultados secundarios incluyeron la fuga anastom&#xf3;tica, la afectaci&#xf3;n del margen de resecci&#xf3;n circunferencial, la calidad del esp&#xe9;cimen, la recurrencia local, las met&#xe1;stasis a distancia, la supervivencia global y la supervivencia libre de enfermedad..RESULTADOS:Se incluy&#xf3; un total de 150 pacientes con una mediana de seguimiento de 32 y 23 meses para la escisi&#xf3;n mesorrectal total transanal primaria y la escisi&#xf3;n local seguida de una escisi&#xf3;n mesorrectal total transanal de complemento, respectivamente. La tasa de colostom&#xed;a terminal fue significativamente menor en el grupo de escisi&#xf3;n local seguida de escisi&#xf3;n mesorrectal total transanal de complemento (21 %) en comparaci&#xf3;n con el grupo de escisi&#xf3;n mesorrectal total transanal primaria (42 %, p = 0.022). Se produjeron m&#xe1;s fugas anastom&#xf3;ticas en el grupo de escisi&#xf3;n local seguida de escisi&#xf3;n mesorrectal transanal total cde complemento (33 % frente a 18 %, p = 0.064). No se observaron diferencias en la afectaci&#xf3;n del margen de resecci&#xf3;n circunferencial ni en la calidad del esp&#xe9;cimen. Las tasas de recidiva local a dos a&#xf1;os fueron del 4 % para la escisi&#xf3;n mesorrectal total transanal primaria y del 3 % para la escisi&#xf3;n local seguida de escisi&#xf3;n mesorrectal total transanal de complemento(p = 0.343), mientras que las met&#xe1;stasis a distancia se produjeron en el 8 % y el 10 % (p = 0.424), respectivamente. No hubo diferencias significativas en la supervivencia global a dos a&#xf1;os (88 % frente a 97 %, p = 0.101) ni en la supervivencia libre de enfermedad a dos a&#xf1;os (82 % frente a 90 %, p = 0.463) entre los grupos.LIMITACIONES:El peque&#xf1;o tama&#xf1;o de la muestra, que impidi&#xf3; la correcci&#xf3;n de las diferencias entre los grupos, y el sesgo de selecci&#xf3;n.CONCLUSI&#xd3;N:Este estudio demostr&#xf3; que la escisi&#xf3;n local seguida de la escisi&#xf3;n transanal total del mesorrecto de complemento para el c&#xe1;ncer rectal cT1-2N0 no aument&#xf3; la tasa de creaci&#xf3;n de colostom&#xed;a terminal ni comprometi&#xf3; los resultados oncol&#xf3;gicos en comparaci&#xf3;n con la escisi&#xf3;n transanal total del mesorrecto primaria en centros con experiencia. ( Traducci&#xf3;n-Dr. Jorge Silva Velazco ).</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Colon and Rectal Surgeons.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Lieshout</LastName><ForeName>Annabel S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moolenaar</LastName><ForeName>Laura R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tobben</LastName><ForeName>Floor F A C</ForeName><Initials>FFAC</Initials><AffiliationInfo><Affiliation>Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Oostendorp</LastName><ForeName>Stefan E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smits</LastName><ForeName>Lisanne J H</ForeName><Initials>LJH</Initials><AffiliationInfo><Affiliation>Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hol</LastName><ForeName>Jeroen C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belgers</LastName><ForeName>Eric H J</ForeName><Initials>EHJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Zuyderland Medical Center, Heerlen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belt</LastName><ForeName>Eric J T</ForeName><Initials>EJT</Initials><AffiliationInfo><Affiliation>Department of Surgery, Department of Surgery, Albert Schweitzer Hospital, Dordrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oosterling</LastName><ForeName>Steven J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Spaarne Gasthuis, Hoofddorp, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sietses</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Surgery, Gelderse Vallei Hospital, Ede, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doornebosch</LastName><ForeName>Pascal G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Department of Surgery, IJsselland Hospital, Capelle a/d Ijssel, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hompes</LastName><ForeName>Roel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuynman</LastName><ForeName>Jurriaan B</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0001-5952-8000</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003125" MajorTopicYN="Y">Colostomy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="Y">Proctectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057868" MajorTopicYN="N">Anastomotic Leak</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072662" MajorTopicYN="N">Margins of Excision</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067368" MajorTopicYN="Y">Transanal Endoscopic Surgery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054047" MajorTopicYN="Y">Surgical Stomas</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000714" MajorTopicYN="N">Anastomosis, Surgical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Completion surgery</Keyword><Keyword MajorTopicYN="N">Early rectal cancer</Keyword><Keyword MajorTopicYN="N">Local excision</Keyword><Keyword MajorTopicYN="N">Stoma</Keyword><Keyword MajorTopicYN="N">Transanal total mesorectal excision</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>18</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>5</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>5</Day><Hour>12</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40323649</ArticleId><ArticleId IdType="pmc">PMC12269642</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003794</ArticleId><ArticleId IdType="pii">00003453-202508000-00009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>integraal kankercentrum Nederland (IKNL) NKN. Cijfers over darmkanker.
https://iknl.nl/kankersoorten/darmkanker/registratie. Accessed October 16, 2024.</Citation></Reference><Reference><Citation>van Lieshout AS, Smits LJH, Sijmons JML, et al. Short-term outcomes after primary total mesorectal excision (TME) versus local excision followed by completion TME for early rectal cancer: population-based propensity-matched study. BJS Open. 2024;8:zrae103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11375580</ArticleId><ArticleId IdType="pubmed">39235090</ArticleId></ArticleIdList></Reference><Reference><Citation>Lezoche E, Paganini AM, Fabiani B, et al. Quality-of-life impairment after endoluminal locoregional resection and laparoscopic total mesorectal excision. Surg Endosc. 2014;28:227&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">24002918</ArticleId></ArticleIdList></Reference><Reference><Citation>Traa MJ, Orsini RG, Den Oudsten BL, et al. Measuring the health-related quality of life and sexual functioning of patients with rectal cancer: does type of treatment matter? Int J Cancer. 2014;134:979&#x2013;987.</Citation><ArticleIdList><ArticleId IdType="pubmed">23934989</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Heijden JAG, Ko&#xeb;ter T, Smits LJH, et al. Functional complaints and quality of life after transanal total mesorectal excision: a meta-analysis. Br J Surg. 2020;107:489&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7155085</ArticleId><ArticleId IdType="pubmed">32154594</ArticleId></ArticleIdList></Reference><Reference><Citation>Borstlap WAA, van Oostendorp SE, Klaver CEL, et al. ; the Research Committee of the European Society of Coloproctology. Organ preservation in rectal cancer: a synopsis of current guidelines. Colorectal Dis. 2017;20:201&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">29136328</ArticleId></ArticleIdList></Reference><Reference><Citation>Backes Y, Elias SG, Groen JN, et al. ; Dutch T1 CRC Working Group. Histologic factors associated with need for surgery in patients with pedunculated T1 colorectal carcinomas. Gastroenterology. 2018;154:1647&#x2013;1659.</Citation><ArticleIdList><ArticleId IdType="pubmed">29366842</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashiguchi Y, Muro K, Saito Y, et al. ; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946738</ArticleId><ArticleId IdType="pubmed">31203527</ArticleId></ArticleIdList></Reference><Reference><Citation>van Oostendorp SE, Smits LJH, Vroom Y, et al. Local recurrence after local excision of early rectal cancer: a meta-analysis of completion TME, adjuvant (chemo)radiation, or no additional treatment. Br J Surg. 2020;107:1719&#x2013;1730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7692925</ArticleId><ArticleId IdType="pubmed">32936943</ArticleId></ArticleIdList></Reference><Reference><Citation>Detering R, van Oostendorp SE, Meyer VM, et al. ; Dutch ColoRectal Audit Group*. MRI cT1-2 rectal cancer staging accuracy: a population-based study. Br J Surg. 2020;107:1372&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7496930</ArticleId><ArticleId IdType="pubmed">32297326</ArticleId></ArticleIdList></Reference><Reference><Citation>Marusch F, Ptok H, Sahm M, et al. Endorectal ultrasound in rectal carcinoma&#x2014;do the literature results really correspond to the realities of routine clinical care? Endoscopy. 2011;43:425&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">21234855</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashraf S, Hompes R, Slater A, et al. ; Association of Coloproctology of Great Britain and Ireland Transanal Endoscopic Microsurgery (TEM) Collaboration. A critical appraisal of endorectal ultrasound and transanal endoscopic microsurgery and decision-making in early rectal cancer. Colorectal Dis. 2012;14:821&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pubmed">21920011</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynne-Jones R, Wyrwicz L, Tiret E, et al. ; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv22&#x2013;iv40.</Citation><ArticleIdList><ArticleId IdType="pubmed">28881920</ArticleId></ArticleIdList></Reference><Reference><Citation>Hompes R, McDonald R, Buskens C, et al. ; Association of Coloproctology of Great Britain and Ireland Transanal Endoscopic Microsurgery Collaboration. Completion surgery following transanal endoscopic microsurgery: assessment of quality and short- and long-term outcome. Colorectal Dis. 2013;15:e576&#x2013;e581.</Citation><ArticleIdList><ArticleId IdType="pubmed">24635913</ArticleId></ArticleIdList></Reference><Reference><Citation>Levic K, Bulut O, Hesselfeldt P, B&#xfc;low S. The outcome of rectal cancer after early salvage TME following TEM compared with primary TME: a case-matched study. Tech Coloproctol. 2013;17:397&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">23192705</ArticleId></ArticleIdList></Reference><Reference><Citation>Serra-Aracil X, Galvez Salda&#xf1;a A, Mora-Lopez LL, et al. Completion surgery in unfavorable rectal cancer after transanal endoscopic microsurgery: does it achieve satisfactory sphincter preservation, quality of total mesorectal excision specimen, and long-term oncological outcomes? Dis Colon Rectum. 2021;64:200&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">33315715</ArticleId></ArticleIdList></Reference><Reference><Citation>Levic Souzani K, Bulut O, Kuhlmann TP, G&#xf6;genur I, Bisgaard T. Completion total mesorectal excision following transanal endoscopic microsurgery does not compromise outcomes in patients with rectal cancer. Surg Endosc. 2022;36:1181&#x2013;1190.</Citation><ArticleIdList><ArticleId IdType="pubmed">33629183</ArticleId></ArticleIdList></Reference><Reference><Citation>Coton C, Lefevre JH, Debove C, et al. Does transanal local resection increase morbidity for subsequent total mesorectal excision for early rectal cancer? Colorectal Dis. 2019;21:15&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">30300969</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid Y, Alves A, Lubrano J, Menahem B. Does previous transanal excision for early rectal cancer impair surgical outcomes and pathologic findings of completion total mesorectal excision? Results of a systematic review of the literature. J Visc Surg. 2018;155:445&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">29657063</ArticleId></ArticleIdList></Reference><Reference><Citation>Piessen G, Cabral C, Benoist S, Penna C, Nordlinger B. Previous transanal full-thickness excision increases the morbidity of radical resection for rectal cancer. Colorectal Dis. 2012;14:445&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">21689342</ArticleId></ArticleIdList></Reference><Reference><Citation>Morino M, Allaix ME, Arolfo S, Arezzo A. Previous transanal endoscopic microsurgery for rectal cancer represents a risk factor for an increased abdominoperineal resection rate. Surg Endosc. 2013;27:3315&#x2013;3321.</Citation><ArticleIdList><ArticleId IdType="pubmed">23479257</ArticleId></ArticleIdList></Reference><Reference><Citation>Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery--the clue to pelvic recurrence? Br J Surg. 1982;69:613&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">6751457</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamina M, Buchs NC, Penna M, Hompes R; St.Gallen Colorectal Consensus Expert Group. St.Gallen consensus on safe implementation of transanal total mesorectal excision. Surg Endosc. 2018;32:1091&#x2013;1103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5807525</ArticleId><ArticleId IdType="pubmed">29234940</ArticleId></ArticleIdList></Reference><Reference><Citation>Veltcamp Helbach M, van Oostendorp SE, Koedam TWA, et al. Structured training pathway and proctoring; multicenter results of the implementation of transanal total mesorectal excision (TaTME) in the Netherlands. Surg Endosc. 2020;34:192&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946716</ArticleId><ArticleId IdType="pubmed">30888498</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzog T, Belyaev O, Chromik AM, et al. TME quality in rectal cancer surgery. Eur J Med Res. 2010;15:292&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3351953</ArticleId><ArticleId IdType="pubmed">20696640</ArticleId></ArticleIdList></Reference><Reference><Citation>Lossius WJ, Stornes T, Myklebust TA, Endreseth BH, Wibe A. Completion surgery vs. primary TME for early rectal cancer: a national study. Int J Colorectal Dis. 2022;37:429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8803686</ArticleId><ArticleId IdType="pubmed">34914000</ArticleId></ArticleIdList></Reference><Reference><Citation>van Gijn W, Brehm V, de Graaf E, et al. Unexpected rectal cancer after TEM: outcome of completion surgery compared with primary TME. Eur J Surg Oncol. 2013;39:1225&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pubmed">23972571</ArticleId></ArticleIdList></Reference><Reference><Citation>Burghgraef TA, Rutgers ML, Leijtens JWA, Tuyman JB, Consten ECJ, Hompes R. Completion total mesorectal excision: a case-matched comparison with primary resection. Ann Surg Open. 2023;4:e327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10513327</ArticleId><ArticleId IdType="pubmed">37746593</ArticleId></ArticleIdList></Reference><Reference><Citation>Koedam TWA, Veltcamp Helbach M, Penna M, et al. Short-term outcomes of transanal completion total mesorectal excision (cTaTME) for rectal cancer: a case-matched analysis. Surg Endosc. 2019;33:103&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6336745</ArticleId><ArticleId IdType="pubmed">29967991</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyatt JNR, Powell SG, Altaf K, Barrow HE, Alfred JS, Ahmed S. Completion total mesorectal excision after transanal local excision of early rectal cancer: a systematic review and meta-analysis. Dis Colon Rectum. 2022;65:628&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">35143429</ArticleId></ArticleIdList></Reference><Reference><Citation>Overwater A, Kessels K, Elias SG, et al. ; Dutch T1 CRC Working Group. Endoscopic resection of high-risk T1 colorectal carcinoma prior to surgical resection has no adverse effect on long-term outcomes. Gut. 2018;67:284&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">27811313</ArticleId></ArticleIdList></Reference><Reference><Citation>Penna M, Hompes R, Arnold S, et al. ; International TaTME Registry Collaborative. Incidence and risk factors for anastomotic failure in 1594 patients treated by transanal total mesorectal excision: results from the international TaTMErRegistry. Ann Surg. 2019;269:700&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">29315090</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi CZ, Gang O, Xiao Li F, et al. Laparoscopic total mesorectal excision versus transanal total mesorectal excision for mid and low rectal cancer: a systematic review and meta-analysis. Medicine (Baltim). 2024;103:e36859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10817019</ArticleId><ArticleId IdType="pubmed">38277570</ArticleId></ArticleIdList></Reference><Reference><Citation>Gang DY, Dong L, DeChun Z, Yichi Z, Ya L. A systematic review and meta-analysis of minimally invasive total mesorectal excision versus transanal total mesorectal excision for mid and low rectal cancer. Front Oncol. 2023;13:1167200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10291686</ArticleId><ArticleId IdType="pubmed">37377919</ArticleId></ArticleIdList></Reference><Reference><Citation>van Oostendorp SE, Koedam TWA, Sietses C, Bonjer HJ, Tuynman JB. Transanal total mesorectal excision compared to laparoscopic TME for mid and low rectal cancer&#x2014;current evidence. Ann Laparosc Endosc Surg. 2018;3:41.</Citation></Reference><Reference><Citation>Nagtegaal ID, van de Velde CJ, van der Worp E, Kapiteijn E, Quirke P, van Krieken JHJM; Cooperative Clinical Investigators of the Dutch Colorectal Cancer Group. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol. 2002;20:1729&#x2013;1734.</Citation><ArticleIdList><ArticleId IdType="pubmed">11919228</ArticleId></ArticleIdList></Reference><Reference><Citation>Quirke P, Steele R, Monson J, et al. ; MRC CR07/NCIC-CTG CO16 Trial Investigators. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet. 2009;373:821&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668948</ArticleId><ArticleId IdType="pubmed">19269520</ArticleId></ArticleIdList></Reference><Reference><Citation>Borstlap WA, Tanis PJ, Koedam TW, et al. A multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer. BMC Cancer. 2016;16:513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4955121</ArticleId><ArticleId IdType="pubmed">27439975</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40300639</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Natural History of Anal Strictures in Pediatric-Onset Crohn's Disease: Long-term Follow-up of a Population-Based Study.</ArticleTitle><Pagination><StartPage>984</StartPage><EndPage>991</EndPage><MedlinePgn>984-991</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003788</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The risk and clinical course of anal stricture observed in Crohn's disease remains poorly known, particularly in pediatric-onset Crohn's disease.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the long-term clinical course of anal stricture in pediatric-onset Crohn's disease using data from a population-based cohort.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A retrospective observational study from a prospective population-based registry.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Population-based study in Northern France.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">All patients with a diagnosis of Crohn's disease before the age of 17 years between 1988 and 2011 within the population-based registry EPIMAD were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Primary outcome was the cumulative risk of anal stricture. Secondary outcomes included include risk of anal cancer, surgery, stoma, and risk factors associated with anal stricture.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1007 patients were included (median age at diagnosis 14.5 years [interquartile range, 12.0-16.1]; median duration of follow-up 8.8 years [interquartile range, 4.6-14.2]). Among them, 1 patient (0.1%) had an anal stricture at diagnosis and 26 (2.6%) had an anal stricture during follow-up. From diagnosis, the 5- and 10-year cumulative incidence of anal stricture at was 0.6% (95% CI, 0.1-1.1) and 1.4% (95% CI, 0.5-2.3), respectively. Twenty-five patients (n = 25/27; 93%) had at least 1 episode of anal ulceration or fistulizing perineal Crohn's disease. In multivariable analysis, extraintestinal manifestations (HR 2.2; 95% CI, 1.0-4.8; p = 0.0270), colonic location (colonic vs ileocolonic HR 1.2; 95% CI, 0.6-2.7; p = 0.0064) and a history of fistulizing perineal Crohn's disease (HR 9.9; 95% CI, 4.3-22.8; p &lt; 0.0001) were significantly associated with anal stricture. After a median follow-up of 6.2 years (2.4-10.6), 11 patients (41%) required at least 1 anal dilation, and healing was observed in 1 patient. One patient (3.7%) had an anal cancer 7 years after stricture diagnosis and 9 patients (33%) needed a stoma. Anal stricture was significantly associated with the need for stoma (HR 5.8; 95% CI, 2.3-14.3; p = 0.0002).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The retrospective design makes the study prone to selection bias and residual confounding.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Within a population-based cohort of pediatric-onset Crohn's diease, the 10-year cumulative incidence of anal stricture was 1.4%, with associations identified with colonic disease location and fistulizing perianal involvement. The presence of an anal stricture was linked to a 5-fold increase in the likelihood of stoma formation. See Video Abstract .</AbstractText><AbstractText Label="HISTORIA NATURAL DE LAS ESTENOSIS ANALES EN LA ENFERMEDAD DE CROHN DE INICIO PEDITRICO SEGUIMIENTO A LARGO PLAZO DE UN ESTUDIO POBLACIONAL" NlmCategory="UNASSIGNED">ANTECEDENTES:El riesgo y la evoluci&#xf3;n cl&#xed;nica de la estenosis anal observada en la enfermedad de Crohn siguen siendo poco conocidos, especialmente en la enfermedad de Crohn de inicio pedi&#xe1;trico.OBJETIVO:Investigar la evoluci&#xf3;n cl&#xed;nica a largo plazo de la estenosis anal en la EC de inicio pedi&#xe1;trico utilizando datos de una cohorte poblacional.DISE&#xd1;O:Estudio observacional retrospectivo a partir de un estudio poblacional prospectivo.ENTORNO CLINICO:Estudio poblacional en el norte de Francia.PACIENTES:Todos los pacientes con diagn&#xf3;stico de enfermedad de Crohn antes de los 17 a&#xf1;os, entre 1988 y 2011, incluidos en el registro poblacional EPIMAD.PRINCIPALES MEDIDAS DE RESULTADOS:La variable principal fue el riesgo acumulado de estenosis anal. Las variables secundarias incluyeron el riesgo de c&#xe1;ncer anal, cirug&#xed;a, estoma y factores de riesgo asociados con la estenosis anal.RESULTADOS:Se incluyeron 1007 pacientes (mediana de edad al diagn&#xf3;stico: 14,5 a&#xf1;os; RIQ: 12,0-16,1), con una mediana de seguimiento de 8,8 a&#xf1;os (RIQ: 4,6-14,2). Un paciente (0,1%) present&#xf3; estenosis anal al diagn&#xf3;stico y 26 (2,6%) durante el seguimiento. Desde el diagn&#xf3;stico, la incidencia acumulada de estenosis anal a los 5 y 10 a&#xf1;os fue del 0,6% (IC del 95%: 0,1-1,1) y del 1,4% (IC del 95%: 0,5-2,3), respectivamente. Veinticinco pacientes (n = 25/27, 93%) presentaron al menos un episodio de ulceraci&#xf3;n anal o enfermedad de Crohn perineal fistulizante. En el an&#xe1;lisis multivariable, las manifestaciones extraintestinales (HR 2,2, IC del 95 %, 1,0-4,8, p = 0,0270), la localizaci&#xf3;n col&#xf3;nica (L2 vs. L3 HR 1,2, IC del 95 %, 0,6-2,7, p = 0,0064) y el antecedente de enfermedad de Crohn perineal fistulizante (HR 9,9, IC del 95 %, 4,3-22,8, p &lt; 0,0001) se asociaron significativamente con la estenosis anal. Tras una mediana de seguimiento de 6,2 a&#xf1;os (2,4-10,6), 11 (41 %) pacientes requirieron al menos una dilataci&#xf3;n anal, y se observ&#xf3; curaci&#xf3;n en un paciente. Un paciente (3,7 %) present&#xf3; c&#xe1;ncer anal 7 a&#xf1;os despu&#xe9;s del diagn&#xf3;stico de la estenosis, y 9 (33 %) pacientes necesitaron un estoma. La estenosis anal se asoci&#xf3; significativamente con la necesidad de estoma (HR 5,8; IC del 95 %: 2,3-14,3; p = 0,0002).LIMITACIONES:El dise&#xf1;o retrospectivo del estudio lo hace propenso a sesgos de selecci&#xf3;n y factores de confusi&#xf3;n residuales.CONCLUSI&#xd3;N:En una cohorte poblacional de pacientes con enfermedad de Crohn de inicio pedi&#xe1;trico, la incidencia acumulada de estenosis anal a 10 a&#xf1;os fue del 1,4 %, con asociaciones identificadas con la localizaci&#xf3;n de la enfermedad col&#xf3;nica y la afectaci&#xf3;n perianal fistulizante. La presencia de estenosis anal est&#xe1; ligada a quintuplicar la probabilidad de formaci&#xf3;n de estoma. (Traducci&#xf3;n- Dr. Francisco M. Abarca-Rendon).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mortreux</LastName><ForeName>Perrine</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leroyer</LastName><ForeName>Ariane</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Economic Health, Lille University Hospital, EPIMAD Registry, Regional House of Clinical Research, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE (Institute for Translational Research in Inflammation), Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ley</LastName><ForeName>Delphine</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE (Institute for Translational Research in Inflammation), Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, CHU Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupont-Lucas</LastName><ForeName>Claire E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Pediatric Gastroenterology, Caen University Hospital, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertrand</LastName><ForeName>Val&#xe9;rie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Le Havre Hospital, Le Havre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillon</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Economic Health, Lille University Hospital, EPIMAD Registry, Regional House of Clinical Research, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE (Institute for Translational Research in Inflammation), Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wils</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE (Institute for Translational Research in Inflammation), Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coevoet</LastName><ForeName>Hugues B</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, H&#xf4;pital Priv&#xe9; Les Bonnettes, Arras, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paupard</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Dunkerque Hospital, Dunkerque, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gower-Rousseau</LastName><ForeName>Corinne</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Reims University Hospital, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siproudhis</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Rennes University Hospital, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Universit&#xe9; de Rouen Normandie, INSERM, ADEN UMR1073, "Nutrition, Inflammation and Microbiota-Gut-Brain Axis," CHU Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turck</LastName><ForeName>Dominique D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE (Institute for Translational Research in Inflammation), Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, CHU Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savoye</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Universit&#xe9; de Rouen Normandie, INSERM, ADEN UMR1073, "Nutrition, Inflammation and Microbiota-Gut-Brain Axis," CHU Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarter</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Economic Health, Lille University Hospital, EPIMAD Registry, Regional House of Clinical Research, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE (Institute for Translational Research in Inflammation), Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fumery</LastName><ForeName>Mathurin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2337-2902</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, Amiens University Hospital, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>EPIMAD Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C536215">Pediatric Crohn's disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="Y">Crohn Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003251" MajorTopicYN="N">Constriction, Pathologic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001004" MajorTopicYN="Y">Anus Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001003" MajorTopicYN="N">Anal Canal</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001005" MajorTopicYN="N">Anus Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anal stricture</Keyword><Keyword MajorTopicYN="N">Crohn&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Perianal Crohn&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Population-based</Keyword><Keyword MajorTopicYN="N">Stoma</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Al Hameedi</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al Khatib</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al Turk</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agoute</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andre</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonietti</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aouakli</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Armand</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Armengol-Debeir</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aroichane</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assi</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aubet</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Auxenfants</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avram</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ayafi-Ramelot</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Azzouzi</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bankovski</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barbry</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bardoux</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baron</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baudet</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bayart</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bazin</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bebahani</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Becqwort</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bellati</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benet</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benali</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benard</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benguigui</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ben Soussan</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bental</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berkelmans</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernet</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernou</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernou-Dron</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertot</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertiaux-Vanda&#xeb;le</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertrand</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Billoud</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biron</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bismuth</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bleuet</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blondel</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blondin</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bobula</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bohon</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bondjemah</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boniface</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonkovski</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonni&#xe8;re</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonvarlet</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonvarlet</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boruchowicz</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bostvironnois</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boualit</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bouazza</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bouche</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boudaillez</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bourgeaux</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bourgeois</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bourguet</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bourienne</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boutaleb</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bouthors</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Branche</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bray</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brazier</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Breban</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bridenne</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brihier</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bril</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brung-Lefebvre</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bulois</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burgiere</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Butel</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Canva</LastName><ForeName>J Y</ForeName><Initials>JY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Canva-Delcambre</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capron</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cardot</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carette</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carpentier</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cartier</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cassar</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cassagnou</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castex</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Catala</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cattan</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Catteau</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caujolle</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cayron</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chandelier</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chantre</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charles</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charneau</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chavance-Thelu</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheny</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chirita</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Choteau</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Claerbout</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clergue</LastName><ForeName>P Y</ForeName><Initials>PY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coevoet</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohen</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Collet</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colin</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colombel</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coopman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cordiez</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corvisart</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cortot</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Couttenier</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crinquette</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crombe</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dadamessi</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daoudi</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dapvril</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davion</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dautreme</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Debas</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Decoster</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Degrave</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dehont</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delatre</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delcenserie</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delesalle</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delette</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delgrange</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delhoustal</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delmotte</LastName><ForeName>J S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Demmane</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deregnaucourt</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Descombes</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desechalliers</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desmet</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desreumaux</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desseaux</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desurmont</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devienne</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devouge</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devred</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devroux</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dewailly</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dharancy</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Di Fiore</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Djedir</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Djedir</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doleh</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dreher-Duwat</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dubois</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duburque</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ducatillon</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duclay</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ducrocq</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ducrot</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ducrotte</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dufilho</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duhamel</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dujardin</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dumant-Forest</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dupas</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dupont</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duranton</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duriez</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duveau</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>El Achkar</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>El Farisi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elie</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elie-Legrand</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elkhaki</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eoche</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Essmaeel</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evrard</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evrard</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fatome</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Filoche</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finet</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flahaut</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flamme</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foissey</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fournier</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foutrein-Comes</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foutrein</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fremond</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frere</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fumery</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gallais</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamblin</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ganga</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerard</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geslin</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gheyssens</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghossini</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghrib</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gilbert</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gillet</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Godart</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Godard</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Godchaux</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Godchaux</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goegebeur</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goria</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gottrand</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gower</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grandmaison</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Groux</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guedon</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guerbeau</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gueroult-Dero</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guillard</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guillem</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guillemot</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guimber</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haddouche</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hakim</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanon</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hautefeuille</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heckestweiller</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hecquet</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hedde</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hellal</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henneresse</LastName><ForeName>P E</ForeName><Initials>PE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heyman</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heraud</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herve</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hochain</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Houssin-Bailly</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Houcke</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huguenin</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iobagiu</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Istanboli</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ivanovic</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iwanicki-Caron</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Janicki</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jarry</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jeu</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joly</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jonas</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jouvenet</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katherin</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerleveo</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khachfe</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kiriakos</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kiriakos</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kohut</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kornhauser</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koutsomanis</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laberenne</LastName><ForeName>J E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacotte</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laffineur</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lagarde</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lalanne</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lalieu</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lannoy</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lapchin</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laprand</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laude</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leblanc</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lecieux</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lecleire</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leclerc</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Couteulx</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ledent</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lefebvre</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lefiliatre</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Goffic</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Legrand</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Grix</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lelong</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leluyer</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lemaitre</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lenaerts</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lepeut</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lepileur</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leplat</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lepoutre-Dujardin</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leroi</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leroy</LastName><ForeName>M Y</ForeName><Initials>MY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Roy</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesage</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesage</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesage</LastName><ForeName>X</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesage</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lescanne-Darchis</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lescut</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lescut</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leurent</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levy</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ley</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lhermie</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Libier</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lion</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lisambert</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loge</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loire</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loreau</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Louf</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Louvet</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lubret</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luciani</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lucidarme</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lugand</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Macaigne</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maetz</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maillard</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mancheron</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manolache</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marks-Brunel</LastName><ForeName>A B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marre</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marti</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marzloff</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathurin</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mauillon</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maunoury</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maupas</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Medam Djomo</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mechior</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Melki</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesnard</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Metayer</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Methari</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meurisse</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meurisse</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michaud</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mirmaran</LastName><ForeName>X</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Modaine</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monthe</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morel</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mortier</LastName><ForeName>P E</ForeName><Initials>PE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moulin</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mouterde</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mozziconaci</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mudry</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nachury</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ngo</LastName><ForeName>M D</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>N'Guyen Khac</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Notteghem</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ollevier</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ostyn</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ouraghi</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oussadou</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ouvry</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paillot</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Painchart</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Panien-Claudot</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paoletti</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Papazian</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parent</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pariente</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paris</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patrier</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paupard</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pauwels</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pauwels</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Penninck</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petit</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piat</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piotte</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plane</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plouvier</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pollet</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pommelet</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pop</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pordes</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pouchain</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prades</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prevost</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prevost</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quartier</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quesnel</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Queuniet</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinton</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rabache</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rabelle</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raclot</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ratajczyk</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rault</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Razemon</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reix</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Renaut-Vantroys</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Revillion</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riachi</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richez</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riault</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roger</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roux</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rudelli</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saber</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Savoye</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schlossberg</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sefrioui</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Segrestin</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seguy</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seminur</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Serin</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seryer</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sevenet</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shekh</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silvie</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simon</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spyckerelle</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Talbodec</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tavernier</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tchandeu</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Techy</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thelu</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thevenin</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thiebault</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thorel</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thuillier</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tielman</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tode</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toisin</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tonnel</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Touchais</LastName><ForeName>J Y</ForeName><Initials>JY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toumelin</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Touze</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tranvouez</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Triplet</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Triki</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turck</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uhlen</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaillant</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valmage</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanco</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandaele-Bertiaux</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandamme</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderbecq</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vander Eecken</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandermolen</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandevenne</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandeville</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandewalle</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandewalle</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaneslander</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanhoove</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanrenterghem</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanveuren</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varlet</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vasies</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verbiese</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verlynde</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vernier-Massouille</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vermelle</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verne</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vezilier-Cocq</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vigneron</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vincendet</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Viot</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Voiment</LastName><ForeName>Y M</ForeName><Initials>YM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wacrenier</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waeghemaecker</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wallez</LastName><ForeName>J Y</ForeName><Initials>JY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wantiez</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wartel</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weber</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Willocquet</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wizla</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolschies</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaharia</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaoui</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zalar</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaouri</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zellweger</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ziade</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>18</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>30</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>29</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40300639</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003788</ArticleId><ArticleId IdType="pii">00003453-202508000-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn&#x2019;s disease. Inflamm Bowel Dis. 2002;8:244&#x2013;250.</Citation></Reference><Reference><Citation>Freeman HJ. Natural history and clinical behavior of Crohn&#x2019;s disease extending beyond two decades. J Clin Gastroenterol. 2003;37:216&#x2013;219.</Citation></Reference><Reference><Citation>Peyrin-Biroulet L, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Perianal Crohn&#x2019;s disease findings other than fistulas in a population-based cohort. Inflamm Bowel Dis. 2012;18:43&#x2013;48.</Citation></Reference><Reference><Citation>Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn&#x2019;s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875&#x2013;880.</Citation></Reference><Reference><Citation>Zhao M, Lo BZS, Vester-Andersen MK, Vind I, Bendtsen F, Burisch J. A 10-year follow-up study of the natural history of perianal Crohn&#x2019;s disease in a Danish population-based inception cohort. Inflamm Bowel Dis. 2019;25:1227&#x2013;1236.</Citation></Reference><Reference><Citation>Keljo DJ, Markowitz J, Langton C, et al. Course and treatment of perianal disease in children newly diagnosed with Crohn&#x2019;s disease. Inflamm Bowel Dis. 2009;15:383&#x2013;387.</Citation></Reference><Reference><Citation>Adler J, Dong S, Eder SJ, Dombkowski KJ; ImproveCareNow Pediatric IBD Learning Health System. Perianal Crohn disease in a large multicenter pediatric collaborative. J Pediatr Gastroenterol Nutr. 2017;64:e117&#x2013;e124.</Citation></Reference><Reference><Citation>Brochard C, Siproudhis L, Wallenhorst T, et al. Anorectal stricture in 102 patients with Crohn&#x2019;s disease: natural history in the era of biologics. Aliment Pharmacol Ther. 2014;40:796&#x2013;803.</Citation></Reference><Reference><Citation>Bouguen G, Siproudhis L, Bretagne JF, Bigard MA, Peyrin-Biroulet L. Nonfistulizing perianal Crohn&#x2019;s disease: clinical features, epidemiology, and treatment. Inflamm Bowel Dis. 2010;16:1431&#x2013;1442.</Citation></Reference><Reference><Citation>Linares L, Moreira LF, Andrews H, Allan RN, Alexander-Williams J, Keighley MR. Natural history and treatment of anorectal strictures complicating Crohn&#x2019;s disease. Br J Surg. 1988;75:653&#x2013;655.</Citation></Reference><Reference><Citation>Gower-Rousseau C, Salomez JL, Dupas JL, et al. Incidence of inflammatory bowel disease in northern France (1988-1990). Gut. 1994;35:1433&#x2013;1438.</Citation></Reference><Reference><Citation>Ley D, Leroyer A, Dupont C, et al.; Epimad Group. New therapeutic strategies have changed the natural history of pediatric Crohn&#x2019;s disease: a two-decade population-based study. Clin Gastroenterol Hepatol. 2022;20:2588&#x2013;2597.e1.</Citation></Reference><Reference><Citation>Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314&#x2013;1321.</Citation></Reference><Reference><Citation>Fernandes MA, Verstraete SG, Garnett EA, Heyman MB. Addition of histology to the paris classification of pediatric Crohn disease alters classification of disease location. J Pediatr Gastroenterol Nutr. 2016;62:242&#x2013;245.</Citation></Reference><Reference><Citation>Mortreux P, Leroyer A, Ley D, et al. Natural history of anal stricture in pediatric-onset Crohn&#x2019;s disease: a two-decades population-based study. J Crohns Colitis. 2023;17:i315&#x2013;i316.</Citation></Reference><Reference><Citation>Wolff BG, Culp CE, Beart RW Jr, Ilstrup DM, Ready RL. Anorectal Crohn&#x2019;s disease. A long-term perspective. Dis Colon Rectum. 1985;28:709&#x2013;711.</Citation></Reference><Reference><Citation>Keighley MR, Allan RN. Current status and influence of operation on perianal Crohn&#x2019;s disease. Int J Colorectal Dis. 1986;1:104&#x2013;107.</Citation></Reference><Reference><Citation>Brochard C, Rabilloud ML, Hamonic S, et al.; Groupe ABERMAD. Natural history of perianal Crohn&#x2019;s disease: long-term follow-up of a population-based cohort. Clin Gastroenterol Hepatol. 2020;20:e102&#x2013;e110.</Citation></Reference><Reference><Citation>Fumery M, Pariente B, Sarter H, et al.; Epimad Group. Long-term outcome of pediatric-onset Crohn&#x2019;s disease: a population-based cohort study. Dig Liver Dis. 2019;51:496&#x2013;502.</Citation></Reference><Reference><Citation>Singh S, Ding NS, Mathis KL, et al. Systematic review with meta-analysis: faecal diversion for management of perianal Crohn&#x2019;s disease. Aliment Pharmacol Ther. 2015;42:783&#x2013;792.</Citation></Reference><Reference><Citation>Burke JP. Role of fecal diversion in complex Crohn&#x2019;s disease. Clin Colon Rectal Surg. 2019;32:273&#x2013;279.</Citation></Reference><Reference><Citation>Hughes LE. Clinical classification of perianal Crohn&#x2019;s disease. Dis Colon Rectum. 1992;35:928&#x2013;932.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40192136</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Controlling Oligopolyposis With Colonoscopy: A Cohort Study.</ArticleTitle><Pagination><StartPage>907</StartPage><EndPage>912</EndPage><MedlinePgn>907-912</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003763</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Oligopolyposis is defined as between 10 and 100 polyps in the large intestine. If the polyps are adenomas, at least 15% of affected patients will have a syndrome of hereditary colorectal cancer predisposition. Management is aimed at preventing the development of cancer, and options include chemoprevention, colectomy, and colonoscopy, with colectomy generally favored. The role of colonoscopy is relatively unexplored.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To present the results of colonoscopic control of patients with oligopolyposis.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective study of a cohort of patients with oligopolyposis separated by genotype and histology.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Hereditary colorectal cancer center.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Those with oligopolyposis preferring management with sequential colonoscopy to colectomy and who underwent at least 3 years of follow-up were included.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Colonoscopy, polypectomy, and surgical resection.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Number of colonoscopies, complications of colonoscopies, length of follow-up, number of polyps at first and last colonoscopy, size of the largest polyp at first and last colonoscopy, incidence and stage of cancer, and timing of the cancer diagnosis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 59 patients: 29 with sessile serrated polyposis, 13 with MUTYH -associated polyposis, 8 with attenuated familial adenomatous polyposis, and 9 with oligopolyposis not otherwise specified. Patients with familial adenomatous polyposis were 20 years younger than those in the other groups. Patients averaged 1 colonoscopy per year for a mean follow-up between 5 and 11 years. One patient had a post-polypectomy hemorrhage, but there was no perforation and no admission. No patient needed surgery to control benign polyposis. Nine patients had cancer, 6 diagnosed and resected before the start of the colonoscopic surveillance. Three patients with sessile serrated polyposis developed interval cancers while on surveillance, all stage 1. These 3 patients were the only ones who needed colectomy.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Relatively low numbers of familial adenomatous polyposis and oligopolyposis patients. Lack of specific data on variants.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In compliant patients and experienced hands, endoscopic control of oligopolyposis can be safe and effective. See Video Abstract .</AbstractText><AbstractText Label="CONTROLANDO LA OLIGOPOLIPOSIS MEDIANTE COLONOSCOPIA UN ESTUDIO DE COHORTE" NlmCategory="UNASSIGNED">ANTECEDENTES:La oligopoliposis se define como la presencia de entre 10 y 100 p&#xf3;lipos en el intestino grueso. En el caso que se trataran de adenomas, al menos el 15% de los pacientes afectados presentar&#xe1; una predisposici&#xf3;n al s&#xed;ndrome hereditario de c&#xe1;ncer colorrectal. El tratamiento se centra en prevenir el desarrollo del c&#xe1;ncer y las opciones incluyen quimioprevenci&#xf3;n, colectom&#xed;a y colonoscopia, siendo la colectom&#xed;a la que generalmente se prefiere. El papel de la colonoscopia es relativamente inexplorado.OBJETIVO:Presentar los resultados del control colonosc&#xf3;pico de pacientes con oligopoliposis.DISE&#xd1;O:Estudio retrospectivo de una cohorte de pacientes con oligopoliposis, separados por genotipo e histolog&#xed;a.ESCENARIO:Centro de c&#xe1;ncer colorrectal hereditario.PACIENTES:Pacientes con oligopoliposis que prefirieron el tratamiento con colonoscopia secuencial a la colectom&#xed;a, y que se sometieron a al menos tres a&#xf1;os de seguimiento.INTERVENCIONES:Colonoscopia y polipectom&#xed;a, resecci&#xf3;n quir&#xfa;rgica.PRINCIPALES MEDIDAS DE RESULTADOS:N&#xfa;mero de colonoscopias, complicaciones de las colonoscopias, duraci&#xf3;n del seguimiento, n&#xfa;mero de p&#xf3;lipos en la primera y &#xfa;ltima colonoscopia, tama&#xf1;o del p&#xf3;lipo m&#xe1;s grande en la primera y &#xfa;ltima colonoscopia, incidencia y estadio del c&#xe1;ncer, y momento del diagn&#xf3;stico.RESULTADOS:Se incluyeron 59 pacientes: 29 con poliposis serrada s&#xe9;sil, 13 con poliposis asociada a MUTYH, 8 con poliposis adenomatosa familiar (PAF) atenuada y 9 con oligopoliposis no especificada. Los pacientes con PAF eran 20 a&#xf1;os m&#xe1;s j&#xf3;venes que los dem&#xe1;s grupos. Los pacientes promediaron una colonoscopia al a&#xf1;o durante una media de seguimiento de entre 5 y 11 a&#xf1;os. Un paciente sufri&#xf3; una hemorragia pospolipectom&#xed;a, pero no se produjo ninguna perforaci&#xf3;n ni ingreso hospitalario. Ning&#xfa;n paciente requiri&#xf3; cirug&#xed;a para controlar la poliposis benigna. Nueve pacientes presentaron c&#xe1;ncer, 6 de ellos diagnosticados y resecados antes del inicio de la vigilancia colonosc&#xf3;pica. Tres pacientes con poliposis serrada s&#xe9;sil desarrollaron c&#xe1;nceres de intervalo durante la vigilancia, todos en estadio 1. Estos fueron los &#xfa;nicos pacientes que necesitaron colectom&#xed;a.LIMITACIONES:N&#xfa;mero relativamente bajo de pacientes con PAF y oligopoliposis. Falta de datos espec&#xed;ficos sobre variantes.CONCLUSIONES:En pacientes cumplidores y con experiencia, el control endosc&#xf3;pico de la oligopoliposis puede ser seguro y eficaz. (Traducci&#xf3;n-Dr Osvaldo Gauto ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Church</LastName><ForeName>James</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3489-4140</Identifier><AffiliationInfo><Affiliation>Global Center for Integrated Colorectal Surgery and IBD Interventional Endoscopy, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003113" MajorTopicYN="Y">Colonoscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003111" MajorTopicYN="Y">Colonic Polyps</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="N">Colectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011125" MajorTopicYN="Y">Adenomatous Polyposis Coli</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000236" MajorTopicYN="Y">Adenoma</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Colonoscopy</Keyword><Keyword MajorTopicYN="N">Familial adenomatous polyposis</Keyword><Keyword MajorTopicYN="N">MUTYH-associated polyposis</Keyword><Keyword MajorTopicYN="N">Oligopolyposis</Keyword><Keyword MajorTopicYN="N">Serrated polyposis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>12</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>7</Day><Hour>13</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>7</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40192136</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003763</ArticleId><ArticleId IdType="pii">00003453-202507000-00017</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Grover S, Kastrinos F, Steyerberg EW, et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA. 2012;308:485&#x2013;492.</Citation></Reference><Reference><Citation>Valle L, Monahan KJ. Genetic predisposition to gastrointestinal polyposis: syndromes, tumour features, genetic testing, and clinical management. Lancet Gastroenterol Hepatol. 2024;9:68&#x2013;82.</Citation></Reference><Reference><Citation>Dekker E, Bleijenberg A, Balaguer F; Dutch-Spanish-British Serrated Polyposis Syndrome collaboration. Update on the World Health Organization criteria for diagnosis of serrated polyposis syndrome. Gastroenterology. 2020;158:1520&#x2013;1523.</Citation></Reference><Reference><Citation>Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW; American College of Gastroenterology. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223&#x2013;262; quiz 263.</Citation></Reference><Reference><Citation>Ishikawa H, Mutoh M, Iwama T, et al. Endoscopic management of familial adenomatous polyposis in patients refusing colectomy. Endoscopy. 2016;48:51&#x2013;55.</Citation></Reference><Reference><Citation>Murano T, Ikematsu H, Shinmura K, et al. Endoscopic management of familial adenomatous polyposis targeting colorectal lesions greater than 5&#x2009;mm in size: a single-center retrospective study. Fam Cancer. 2023;22:83&#x2013;89.</Citation></Reference><Reference><Citation>Valent&#xed;n F, Guarinos C, Ju&#xe1;rez M, et al. Endoscopic surveillance in patients with multiple (10-100) colorectal polyps. Endoscopy. 2016;48:56&#x2013;61.</Citation></Reference><Reference><Citation>Abbass MA, Leach B, Church JM. The second allele: a key to understanding the timing of sporadic and hereditary colorectal tumorigenesis. Genes. 2021;12:1515.</Citation></Reference><Reference><Citation>Liang J, Kalady MF, Church J. Snaring large, serrated polyps. Surg Endosc. 2013;27:1622&#x2013;1627.</Citation></Reference><Reference><Citation>Knudsen AL, Bisgaard ML, B&#xfc;low S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer. 2003;2:43&#x2013;55.</Citation></Reference><Reference><Citation>Kaz AM, Dominitz JA. Can individuals with colonic polyposis be managed safely with colonoscopic surveillance? Endoscopy. 2016;48:7&#x2013;8.</Citation></Reference><Reference><Citation>Church J, Erkan A. Scope or scalpel? A matched study of the treatment of large colorectal polyps. ANZ J Surg. 2018;88:177&#x2013;181.</Citation></Reference><Reference><Citation>Urso EDL, Celotto F, Giandomenico F, et al. Analysis of morbidity and mortality, quality of life and bowel function after total colectomy with ileorectal anastomosis versus right and left hemicolectomy: a study to optimise the treatment of Lynch syndrome and attenuated polyposis coli. Eur J Surg Oncol. 2020;46:1613&#x2013;1619.</Citation></Reference><Reference><Citation>Duclos J, Lefevre JH, Lefran&#xe7;ois M, et al. Immediate outcome, long-term function and quality of life after extended colectomy with ileorectal or ileosigmoid anastomosis. Colorectal Dis. 2014;16:O288&#x2013;O296.</Citation></Reference><Reference><Citation>Church J. Being a colonoscopist. Dis Colon Rectum. 2023;66:1294&#x2013;1296.</Citation></Reference><Reference><Citation>Heald B, Hampel H, Church J, et al.; Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. Collaborative Group of the Americas on Inherited Gastrointestinal Cancer position statement on multigene panel testing for patients with colorectal cancer and/or polyposis. Fam Cancer. 2020;19:223&#x2013;239.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39847799</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Incidence and Risk Factors for Nonreversal of Stoma in Patients With Crohn's Disease: A Single-Center Study.</ArticleTitle><Pagination><StartPage>217</StartPage><EndPage>226</EndPage><MedlinePgn>217-226</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003542</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Even in the biological era, permanent stoma is not uncommon in patients with Crohn's Disease.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to investigate the incidence and risk factors of permanent stoma in Crohn's disease patients and provide clinical evidence for reducing this disabling outcome.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Consecutive patients with Crohn's disease who underwent ostomies in the past decade were reviewed.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">The study was conducted in a tertiary referral hospital.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Four hundred fifty-seven patients with Crohn's disease were divided into temporary stoma and permanent stoma groups based on stoma reversal or not. A permanent stoma was defined as a stoma that had not been reversed or closed for at least 2 years.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The incidence, risk factors, and long-term outcomes of permanent stomas were reported.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The rate of permanent stoma was 4.0% in our surgical cohort. The mean age at the time of permanent stoma creation was 36.0 (28.0-45.0) years. The annual incidence of permanent stoma had declined significantly in the past 10 years (p = 0.033). Our study showed that the independent risk factors for permanent stoma formation included female sex, previous operation for Crohn's disease, the presence of rectal disease, subtotal colectomy, and rectal resection. Interestingly, long-term follow-up found that the active distal colorectal lesion was independently associated with the requirement of subsequent surgery.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The study was limited by its retrospective nature.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although the incidence of permanent stoma in patients with Crohn's disease showed a downward trend in the past 10 years, effective treatments based on relevant risk factors should be used to prevent permanent stoma and control subsequent surgical recurrence. See Video Abstract.</AbstractText><AbstractText Label="INCIDENCIA Y FACTORES DE RIESGO DE NO REVERSIN DEL ESTOMA EN PACIENTES CON ENFERMEDAD DE CROHN ESTUDIO DE UN SOLO CENTRO" NlmCategory="UNASSIGNED">ANTECEDENTES:Incluso en la era biol&#xf3;gica, el estoma permanente no es poco com&#xfa;n en pacientes con enfermedad de Crohn.OBJETIVO:Este estudio tuvo como objetivo investigar la incidencia y los factores de riesgo del estoma permanente en pacientes con enfermedad de Crohn y proporcionar evidencia cl&#xed;nica para reducir este resultado discapacitante.DISE&#xd1;O:Se revisaron pacientes consecutivos con enfermedad de Crohn que se sometieron a ostom&#xed;as en la &#xfa;ltima d&#xe9;cada.ESCENARIO:El estudio se realiz&#xf3; en un hospital de referencia terciario.PACIENTES:457 pacientes con enfermedad de Crohn se dividieron en los grupos de estoma temporal y estoma permanente seg&#xfa;n si se hab&#xed;a revertido o no el estoma. Un estoma permanente se defini&#xf3; como un estoma que no se hab&#xed;a revertido o cerrado durante al menos dos a&#xf1;os.PRINCIPALES MEDIDAS DE RESULTADOS:Se inform&#xf3; la incidencia, los factores de riesgo y los resultados a largo plazo de los estomas permanentes.RESULTADOS:La tasa de estoma permanente fue del 4,0 % en nuestra cohorte quir&#xfa;rgica. La edad media en el momento de la creaci&#xf3;n del estoma permanente fue de 36,0 (28,0-45,0) a&#xf1;os. La incidencia anual de estomas permanentes hab&#xed;a disminuido significativamente en los &#xfa;ltimos 10 a&#xf1;os (p = 0,033). Nuestro estudio mostr&#xf3; que los factores de riesgo independientes para la formaci&#xf3;n de estomas permanentes inclu&#xed;an el sexo femenino, la cirug&#xed;a previa para la enfermedad de Crohn, la presencia de enfermedad rectal, la colectom&#xed;a subtotal y la resecci&#xf3;n rectal. Curiosamente, el seguimiento a largo plazo encontr&#xf3; que la enfermedad colorrectal distal activa se asoci&#xf3; de forma independiente con la necesidad de una cirug&#xed;a posterior.LIMITACIONES:El estudio estuvo limitado por su naturaleza retrospectiva.CONCLUSIONES:Aunque la incidencia de estomas permanentes en pacientes con enfermedad de Crohn mostr&#xf3; una tendencia descendente en los &#xfa;ltimos 10 a&#xf1;os, se deben utilizar tratamientos efectivos basados en factores de riesgo relevantes para prevenir el estoma permanente y controlar la recurrencia quir&#xfa;rgica posterior. (Traducci&#xf3;n-Dr. Felipe Bellolio).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shixian</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0000-8534-8863</Identifier><AffiliationInfo><Affiliation>Department of General Surgery, Jinling Medical School of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Kangling</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Jinling Medical School of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Jianfeng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Weiming</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Jinling Medical School of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-9315-7282</Identifier><AffiliationInfo><Affiliation>Department of General Surgery, Jinling Medical School of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="Y">Crohn Disease</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054047" MajorTopicYN="Y">Surgical Stomas</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007081" MajorTopicYN="Y">Ileostomy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="N">Colectomy</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>24</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>23</Day><Hour>18</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>23</Day><Hour>17</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39847799</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003542</ArticleId><ArticleId IdType="pii">00003453-202502000-00014</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhao M, Gonczi L, Lakatos PL, Burisch J. The burden of inflammatory bowel disease in Europe in 2020. J Crohns Colitis. 2021;15:1573&#x2013;1587.</Citation></Reference><Reference><Citation>Hirsch A, Yarur AJ, Dezheng H, et al. Penetrating disease, narcotic use, and loop ostomy are associated with ostomy and IBD-related complications after ostomy surgery in Crohn&#x2019;s disease patients. J Gastrointest Surg. 2015;19:1852&#x2013;1861.</Citation></Reference><Reference><Citation>Ambe PC, Kurz NR, Nitschke C, Odeh SF, M&#xf6;slein G, Zirngibl H. Intestinal ostomy: classification, indications, ostomy care and complication management. Dtsch Arztebl Int. 2018;115:182&#x2013;187.</Citation></Reference><Reference><Citation>Pandiaraja J, Chakkarapani R, Arumugam S. A study on patterns, indications, and complications of an enteric stoma. J Family Med Prim Care. 2021;10:3277&#x2013;3282.</Citation></Reference><Reference><Citation>Mueller MH, Geis M, Glatzle J, et al. Risk of fecal diversion in complicated perianal Crohn&#x2019;s disease. J Gastrointest Surg. 2007;11:529&#x2013;537.</Citation></Reference><Reference><Citation>Guillem JG, Roberts PL, Murray JJ, Coller JA, Veidenheimer MC, Schoetz DJ. Factors predictive of persistent or recurrent Crohn&#x2019;s disease in excluded rectal segments. Dis Colon Rectum. 1992;35:768&#x2013;772.</Citation></Reference><Reference><Citation>Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB; American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn&#x2019;s disease. Gastroenterology. 2003;125:1508&#x2013;1530.</Citation></Reference><Reference><Citation>Everhov AH, Kalman TD, S&#xf6;derling J, et al. Probability of stoma in incident patients with Crohn&#x2019;s disease in Sweden 2003-2019: a population-based study. Inflamm Bowel Dis. 2022;28:1160&#x2013;1168.</Citation></Reference><Reference><Citation>Ma C, Almutairdi A, Tanyingoh D, et al. Reduction in surgical stoma rates in Crohn&#x2019;s disease: a population&#x2010;based time trend analysis. Colorectal Dis. 2019;21:1279&#x2013;1287.</Citation></Reference><Reference><Citation>Coscia M, Gentilini L, Laureti S, et al. Risk of permanent stoma in extensive Crohn&#x2019;s colitis: the impact of biological drugs. Colorectal Dis. 2013;15:1115&#x2013;1122.</Citation></Reference><Reference><Citation>Abdalla MI, Sandler RS, Kappelman MD, et al. The impact of ostomy on quality of life and functional status of Crohn&#x2019;s disease patients. Inflamm Bowel Dis. 2016;22:2658&#x2013;2664.</Citation></Reference><Reference><Citation>Galandiuk S, Kimberling J, Al-Mishlab TG, Stromberg AJ. Perianal Crohn disease: predictors of need for permanent diversion. Ann Surg. 2005;241:796&#x2013;801.</Citation></Reference><Reference><Citation>Fumery M, Dulai PS, Meirick P, et al. Systematic review with meta&#x2010;analysis: recurrence of Crohn&#x2019;s disease after total colectomy with permanent ileostomy. Aliment Pharmacol Ther. 2017;45:381&#x2013;390.</Citation></Reference><Reference><Citation>Lopez J, Konijeti GG, Nguyen DD, Sauk J, Yajnik V, Ananthakrishnan AN. Natural history of Crohn&#x2019;s disease following total colectomy and end ileostomy. Inflamm Bowel Dis. 2014;20:1236&#x2013;1241.</Citation></Reference><Reference><Citation>Crowell KT, Messaris E. Risk factors and implications of anastomotic complications after surgery for Crohn&#x2019;s disease. World J Gastrointest Surg. 2015;7:237&#x2013;242.</Citation></Reference><Reference><Citation>Bernell O, Lapidus A, Hellers G. Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn&#x2019;s disease. Br J Surg. 2000;87:1697&#x2013;1701.</Citation></Reference><Reference><Citation>Russo E, Cinci L, Di Gloria L, et al. Crohn&#x2019;s disease recurrence updates: first surgery vs. surgical relapse patients display different profiles of ileal microbiota and systemic microbial-associated inflammatory factors. Front Immunol. 2022;13:886468.</Citation></Reference><Reference><Citation>Koriche D, Gower-Rousseau C, Chater C, et al. Post-operative recurrence of Crohn&#x2019;s disease after definitive stoma: an underestimated risk. Int J Colorectal Dis. 2017;32:453&#x2013;458.</Citation></Reference><Reference><Citation>Ma C, Kotze PG, Almutairdi A, et al. DOP039 Exploring stoma rates in Crohn&#x2019;s disease in the biologic era: a population-based time trend analysis. J Crohns Colitis. 2018;12(suppl 1):S057&#x2013;S058.</Citation></Reference><Reference><Citation>Lamb CA, Kennedy NA, Raine T, et al.; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(suppl 3):s1&#x2013;s106.</Citation></Reference><Reference><Citation>Meima-van Praag EM, Buskens CJ, Hompes R, Bemelman WA. Surgical management of Crohn&#x2019;s disease: a state of the art review. Int J Colorectal Dis. 2021;36:1133&#x2013;1145.</Citation></Reference><Reference><Citation>Adamina M, Bonovas S, Raine T, et al. ECCO guidelines on therapeutics in Crohn&#x2019;s disease: surgical treatment. J Crohns Colitis. 2020;14:155&#x2013;168.</Citation></Reference><Reference><Citation>Bafford AC, Latushko A, Hansraj N, Jambaulikar G, Ghazi LJ. The use of temporary fecal diversion in colonic and perianal Crohn&#x2019;s disease does not improve outcomes. Dig Dis Sci. 2017;62:2079&#x2013;2086.</Citation></Reference><Reference><Citation>Takahashi K, Funayama Y, Fukushima K, et al. Stoma-related complications in inflammatory bowel disease. Dig Surg. 2008;25:16&#x2013;20.</Citation></Reference><Reference><Citation>Aboulian A. Ostomy complications in Crohn&#x2019;s disease. Clin Colon Rectal Surg. 2019;32:314&#x2013;322.</Citation></Reference><Reference><Citation>Estrada DML, Benghi LM, Kotze PG. Practical insights into stomas in inflammatory bowel disease: what every healthcare provider needs to know. Curr Opin Gastroenterol. 2021;37:320&#x2013;327.</Citation></Reference><Reference><Citation>Bianchi R, Mamadou-Path&#xe9; B, von K&#xe4;nel R, et al.; or the Swiss IBD cohort study. Effect of closed and permanent stoma on disease course, psychological well-being and working capacity in Swiss IBD cohort study patients. PLoS One. 2022;17:e0274665.</Citation></Reference><Reference><Citation>Blackwell J, Saxena S, Jayasooriya N, et al. P86 Permanent stoma formation in Crohn&#x2019;s disease is associated with increased rates of antidepressant use. Gut. 2021;70(suppl 1):A85.</Citation></Reference><Reference><Citation>Blackwell J, Saxena S, Jayasooriya N, et al.; POP-IBD Study Group. Stoma formation in Crohn&#x2019;s disease and the likelihood of antidepressant use: a population-based cohort study. Clin Gastroenterol Hepatol. 2022;20:e703&#x2013;e710.</Citation></Reference><Reference><Citation>Singh S, Ding NS, Mathis KL, et al. Systematic review with meta&#x2010;analysis: faecal diversion for management of perianal Crohn&#x2019;s disease. Aliment Pharmacol Ther. 2015;42:783&#x2013;792.</Citation></Reference><Reference><Citation>Burke JP. Role of fecal diversion in complex Crohn&#x2019;s disease. Clin Colon Rectal Surg. 2019;32:273&#x2013;279.</Citation></Reference><Reference><Citation>Ozgur I, Kulle CB, Buyuk M, et al. What are the predictors for recurrence of Crohn&#x2019;s disease after surgery? Medicine (Baltim). 2021;100:e25340.</Citation></Reference><Reference><Citation>Taleban S, Van Oijen MGH, Vasiliauskas EA, et al. Colectomy with permanent end ileostomy is more cost-effective than ileal pouch-anal anastomosis for Crohn&#x2019;s colitis. Dig Dis Sci. 2016;61:550&#x2013;559.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38653493</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Cytological Analysis of the Surgical Field During Transanal Total Mesorectal Excision for Rectal Cancer: A Prospective Study.</ArticleTitle><Pagination><StartPage>1009</StartPage><EndPage>1017</EndPage><MedlinePgn>1009-1017</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003300</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">An unexpectedly large number of patients experienced local recurrence with transanal total mesorectal excision in Norway. This appears to be associated with cancer cell spillage during surgery.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the surgical field cytology during transanal total mesorectal excision.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">This was a prospective cohort study.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">This study was conducted at a single center between June and December 2020.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Forty patients with rectal cancer underwent transanal total mesorectal excision. After irrigation of the surgical field, the water specimens were cytologically evaluated at 6 representative steps. The first sample was used as an initial control. The second, third, fourth, fifth, and sixth samples were collected after the first pursestring suture, rectotomy, the second pursestring suture, specimen resection, and anastomosis, respectively. The clinicopathological features and intraoperative complications of the patients were reviewed.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The primary outcome was to evaluate the presence of cancer cells in washing cytological samples.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 40 consecutive patients enrolled in this study, 18 patients underwent neoadjuvant chemoradiotherapy. Incomplete first pursestring suture and rectal perforation were observed in 4 (10.0%) and 3 (7.5%) cases, respectively. In the first sample, 31 patients (77.5%) had malignant cells. Malignant findings were detected in 2 patients (5.0%) from the second to fifth samples. None of the sixth sample exhibited any malignant findings.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">This single-center study had a small sample size.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Cancer cells were initially detected by cytology, but only a few were observed throughout the procedure; however, cancer cells were not detected in the final surgical field. Further follow-up and novel studies are required to obtain clinically significant findings using cytology during transanal total mesorectal excision. See Video Abstract .</AbstractText><AbstractText Label="ANLISIS CITOLGICO DEL CAMPO QUIRRGICO DURANTE LA ESCISIN TOTAL DEL MESORRECTO TRANSANAL PARA EL CNCER DE RECTO UN ESTUDIO PROSPECTIVO" NlmCategory="UNASSIGNED">ANTECEDENTES:Un n&#xfa;mero inesperadamente grande de pacientes experiment&#xf3; recurrencia local con la escisi&#xf3;n total del mesorrecto transanal en Noruega. Esto parece estar asociado con el derrame de c&#xe9;lulas cancerosas durante la cirug&#xed;a.OBJETIVO:Investigar la citolog&#xed;a del campo quir&#xfa;rgico durante la escisi&#xf3;n total del mesorrecto transanal.DISE&#xd1;O:Este fue un estudio de cohorte prospectivo.ENTORNO CLINICO:Este estudio se realiz&#xf3; en un solo centro entre junio y diciembre de 2020.PACIENTES:Cuarenta pacientes con c&#xe1;ncer de recto se sometieron a escisi&#xf3;n total del mesorrecto transanal. Despu&#xe9;s de la irrigaci&#xf3;n del campo quir&#xfa;rgico, las muestras de agua se evaluaron citol&#xf3;gicamente en seis pasos representativos. La primera muestra se utiliz&#xf3; como control inicial. La segunda, tercera, cuarta, quinta y sexta muestras se recolectaron despu&#xe9;s de la primera sutura en bolsa de tabaco, la rectotom&#xed;a, la segunda sutura en bolsa de tabaco, la resecci&#xf3;n de la muestra y la anastomosis, respectivamente. Se revisaron las caracter&#xed;sticas cl&#xed;nico-patol&#xf3;gicas y las complicaciones intraoperatorias de los pacientes.PRINCIPALES MEDIDAS DE RESULTADO:El resultado primario fue evaluar la presencia de c&#xe9;lulas cancerosas en el lavado de muestras citol&#xf3;gicas.RESULTADOS:De los 40 pacientes consecutivos inscritos en este estudio, 18 pacientes se sometieron a quimiorradioterapia neoadyuvante. Se observaron la primera sutura en bolsa de tabaco incompleta y perforaci&#xf3;n rectal en cuatro (10,0%) y tres (7,5%) casos, respectivamente. En la primera muestra, 31 (77,5%) pacientes ten&#xed;an c&#xe9;lulas malignas. Se detectaron hallazgos malignos en dos pacientes (5,0%) de la segunda a la quinta muestra. Ninguno de la sexta muestra demostraron hallazgos malignos.LIMITACIONES:Este estudio unic&#xe9;ntrico tuvo un tama&#xf1;o de muestra peque&#xf1;o.CONCLUSIONES:Inicialmente se detectaron c&#xe9;lulas cancerosas mediante citolog&#xed;a, pero solo se observaron unas pocas durante todo el procedimiento; sin embargo, no se detectaron c&#xe9;lulas cancerosas en el campo quir&#xfa;rgico final. Se requieren m&#xe1;s seguimientos y estudios novedosos para obtener hallazgos cl&#xed;nicamente significativos mediante citolog&#xed;a durante la escisi&#xf3;n total del mesorrecto transanal. (Traducci&#xf3;n- Dr. Francisco M. Abarca-Rendon ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Yushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital East, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Hiro</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital East, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital East, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teramura</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital East, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsukada</LastName><ForeName>Yuichiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital East, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasaki</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital East, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kojima</LastName><ForeName>Motohiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Masaaki</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1101-2707</Identifier><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital East, Chiba, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="Y">Proctectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067368" MajorTopicYN="N">Transanal Endoscopic Surgery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009664" MajorTopicYN="N" Type="Geographic">Norway</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>18</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>24</Day><Hour>1</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>23</Day><Hour>20</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38653493</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003300</ArticleId><ArticleId IdType="pii">00003453-202408000-00006</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sylla P, Rattner DW, Delgado S, Lacy AM. NOTES transanal rectal cancer resection using transanal endoscopic microsurgery and laparoscopic assistance. Surg Endosc. 2010;24:1205&#x2013;1210.</Citation></Reference><Reference><Citation>Imai S, Ito M. A novel surgical training simulator for transanal total mesorectal excision. Tech Coloproctol. 2020;24:1163&#x2013;1168.</Citation></Reference><Reference><Citation>Lacy AM, Tasende MM, Delgado S, et al. Transanal total mesorectal excision for rectal cancer: outcomes after 140 patients. J Am Coll Surg. 2015;221:415&#x2013;423.</Citation></Reference><Reference><Citation>Penna M, Hompes R, Arnold S, et al.; International TaTME Registry Collaborative. Incidence and risk factors for anastomotic failure in 1594 patients treated by transanal total mesorectal excision: results from the international TaTME registry. Ann Surg. 2019;269:700&#x2013;711.</Citation></Reference><Reference><Citation>Perdawood SK, Thinggaard BS, Bjoern MX. Effect of transanal total mesorectal excision for rectal cancer: comparison of short-term outcomes with laparoscopic and open surgeries. Surg Endosc. 2018;32:2312&#x2013;2321.</Citation></Reference><Reference><Citation>Zeng Z, Luo S, Chen J, Cai Y, Zhang X, Kang L. Comparison of pathological outcomes after transanal versus laparoscopic total mesorectal excision: a prospective study using data from randomized control trial. Surg Endosc. 2020;34:3956&#x2013;3962.</Citation></Reference><Reference><Citation>Burke JP, Martin-Perez B, Khan A, et al. Transanal total mesorectal excision for rectal cancer: early outcomes in 50 consecutive patients. Colorectal Dis. 2016;18:570&#x2013;577.</Citation></Reference><Reference><Citation>Serra-Aracil X, Zarate A, Bargall&#xf3; J, et al.; Ta-LaTME study Group. Transanal versus laparoscopic total mesorectal excision for mid and low rectal cancer (Ta-LaTME study): multicentre, randomized, open-label trial. Br J Surg. 2023;110:150&#x2013;158.</Citation></Reference><Reference><Citation>Liu H, Zeng Z, Zhang H, et al.; Chinese Transanal Endoscopic Surgery Collaborative (CTESC) Group. Morbidity, mortality, and pathologic outcomes of transanal versus laparoscopic total mesorectal excision for rectal cancer short-term outcomes from a multicenter randomized controlled trial. Ann Surg. 2023;277:1&#x2013;6.</Citation></Reference><Reference><Citation>Penna M, Hompes R, Arnold S, et al.; TaTME Registry Collaborative. Transanal total mesorectal excision: international registry results of the first 720 cases. Ann Surg. 2017;266:111&#x2013;117.</Citation></Reference><Reference><Citation>van der Pas MH, Haglind E, Cuesta MA, et al.; COlorectal cancer Laparoscopic or Open Resection II (COLOR II) Study Group. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol. 2013;14:210&#x2013;218.</Citation></Reference><Reference><Citation>Jeong SY, Park JW, Nam BH, et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15:767&#x2013;774.</Citation></Reference><Reference><Citation>Stevenson AR, Solomon MJ, Lumley JW, et al.; ALaCaRT Investigators. Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: the ALaCaRT randomized clinical trial. JAMA. 2015;314:1356&#x2013;1363.</Citation></Reference><Reference><Citation>Fleshman J, Branda M, Sargent DJ, et al. Effect of laparoscopic-assisted resection vs open resection of stage II or III rectal cancer on pathologic outcomes: the ACOSOG Z6051 randomized clinical trial. JAMA. 2015;314:1346&#x2013;1355.</Citation></Reference><Reference><Citation>Larsen SG, Pfeffer F, Korner H; Norwegian Colorectal Cancer Group. Norwegian moratorium on transanal total mesorectal excision. Br J Surg. 2019;106:1120&#x2013;1121.</Citation></Reference><Reference><Citation>Wasmuth HH, Faerden AE, Myklebust TA, et al.; Norwegian TaTME Collaborative Group, on behalf of the Norwegian Colorectal Cancer Group. Transanal total mesorectal excision for rectal cancer has been suspended in Norway. Br J Surg. 2020;107:121&#x2013;130.</Citation></Reference><Reference><Citation>Matsuda A, Kishi T, Musso G, et al. The effect of intraoperative rectal washout on local recurrence after rectal cancer surgery: a meta-analysis. Ann Surg Oncol. 2013;20:856&#x2013;863.</Citation></Reference><Reference><Citation>Moosvi SR, Manley K, Hernon J. The effect of rectal washout on local recurrence following rectal cancer surgery. Ann R Coll Surg Engl. 2018;100:146&#x2013;151.</Citation></Reference><Reference><Citation>Okoshi K, Kono E, Tomizawa Y, Kinoshita K. Can rectal washout reduce anastomotic recurrence after anterior resection for rectal cancer? A review of the literature. Surg Today. 2020;50:644&#x2013;649.</Citation></Reference><Reference><Citation>Bosanquet DC, Harris DA, Evans MD, Beynon J. Systematic review and meta-analysis of intraoperative peritoneal lavage for colorectal cancer staging. Br J Surg. 2013;100:853&#x2013;862.</Citation></Reference><Reference><Citation>Passot G, Mohkam K, Cotte E, Glehen O. Intra-operative peritoneal lavage for colorectal cancer. World J Gastroenterol. 2014;20:1935&#x2013;1939.</Citation></Reference><Reference><Citation>Papanicolaou GN. Atlas of Exfoliative Cytology. Massachusetts: Harvard University Press; 1954:20&#x2013;21.</Citation></Reference><Reference><Citation>Nishikawa T, Watanabe T, Sunami E, Tsuno NH, Kitayama J, Nagawa H. Prognostic value of peritoneal cytology and the combination of peritoneal cytology and peritoneal dissemination in colorectal cancer. Dis Colon Rectum. 2009;52:2016&#x2013;2021.</Citation></Reference><Reference><Citation>Noura S, Ohue M, Seki Y, Yano M, Ishikawa O, Kameyama M. Long-term prognostic value of conventional peritoneal lavage cytology in patients undergoing curative colorectal cancer resection. Dis Colon Rectum. 2009;52:1312&#x2013;1320.</Citation></Reference><Reference><Citation>Katoh H, Yamashita K, Sato T, Ozawa H, Nakamura T, Watanabe M. Prognostic significance of peritoneal tumour cells identified at surgery for colorectal cancer. Br J Surg. 2009;96:769&#x2013;777.</Citation></Reference><Reference><Citation>Hol JC, van Oostendorp SE, Tuynman JB, Sietses C. Long-term oncological results after transanal total mesorectal excision for rectal carcinoma. Tech Coloproctol. 2019;23:903&#x2013;911.</Citation></Reference><Reference><Citation>Deijen CL, Tsai A, Koedam TW, et al. Clinical outcomes and case volume effect of transanal total mesorectal excision for rectal cancer: a systematic review. Tech Coloproctol. 2016;20:811&#x2013;824.</Citation></Reference><Reference><Citation>Veltcamp Helbach M, Deijen CL, Velthuis S, Bonjer HJ, Tuynman JB, Sietses C. Transanal total mesorectal excision for rectal carcinoma: short-term outcomes and experience after 80 cases. Surg Endosc. 2016;30:464&#x2013;470.</Citation></Reference><Reference><Citation>de&#x2019;Angelis N, Portigliotti L, Azoulay D, Brunetti F. Transanal total mesorectal excision for rectal cancer: a single center experience and systematic review of the literature. Langenbecks Arch Surg. 2015;400:945&#x2013;959.</Citation></Reference><Reference><Citation>Lelong B, Meillat H, Zemmour C, et al. Short- and mid-term outcomes after endoscopic transanal or laparoscopic transabdominal total mesorectal excision for low rectal cancer: a single institutional case-control study. J Am Coll Surg. 2017;224:917&#x2013;925.</Citation></Reference><Reference><Citation>de Cuba EM, Kwakman R, van Egmond M, et al. Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer: future possibilities for personalised treatment by use of biomarkers. Virchows Arch. 2012;461:231&#x2013;243.</Citation></Reference><Reference><Citation>Sugarbaker PH. Update on the prevention of local recurrence and peritoneal metastases in patients with colorectal cancer. World J Gastroenterol. 2014;20:9286&#x2013;9291.</Citation></Reference><Reference><Citation>Klaver CEL, van Huijgevoort NCM, de Buck van Overstraeten A, et al. Locally advanced colorectal cancer: true peritoneal tumor penetration is associated with peritoneal metastases. Ann Surg Oncol. 2018;25:212&#x2013;220.</Citation></Reference><Reference><Citation>Goligher JC, Dukes CE, Bussey HJ. Local recurrences after sphincter saving excisions for carcinoma of the rectum and rectosigmoid. Br J Surg. 1951;39:199&#x2013;211.</Citation></Reference><Reference><Citation>Kodeda K, Holmberg E, Jorgren F, Nordgren S, Lindmark G. Rectal washout and local recurrence of cancer after anterior resection. Br J Surg. 2010;97:1589&#x2013;1597.</Citation></Reference><Reference><Citation>Zhou C, Ren Y, Li J, Li X, He J, Liu P. Systematic review and meta-analysis of rectal washout on risk of local recurrence for cancer. J Surg Res. 2014;189:7&#x2013;16.</Citation></Reference><Reference><Citation>Zhou C, Ren Y, Li J, et al. Association between irrigation fluids, washout volumes and risk of local recurrence of anterior resection for rectal cancer: a meta-analysis of 427 cases and 492 controls. PLoS One. 2014;9:e95699.</Citation></Reference><Reference><Citation>Siddiqi N, Abbas M, Iqbal Z, Farooq M, Conti J, Parvaiz A. Benefit of rectal washout for anterior resection and left sided resections. Int J Surg. 2016;25:106&#x2013;108.</Citation></Reference><Reference><Citation>Maeda K, Maruta M, Hanai T, Sato H, Horibe Y. Irrigation volume determines the efficacy of &#x201c;rectal washout.&#x201d;. Dis Colon Rectum. 2004;47:1706&#x2013;1710.</Citation></Reference><Reference><Citation>Erlandsson J, Holm T, Pettersson D, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017;18:336&#x2013;346.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">38183208</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1757-9767</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Global health promotion</Title><ISOAbbreviation>Glob Health Promot</ISOAbbreviation></Journal><ArticleTitle>G&#xe9;nero, infodemia y desinformaci&#xf3;n en salud. Revisi&#xf3;n de alcance global, vac&#xed;os de conocimiento y recomendaciones.</ArticleTitle><Pagination><StartPage>70</StartPage><EndPage>79</EndPage><MedlinePgn>70-79</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/17579759231216945</ELocationID><Abstract><AbstractText Label="OBJETIVO" NlmCategory="UNASSIGNED">explorar el estado de la literatura cient&#xed;fica sobre los aspectos de infodemia y desinformaci&#xf3;n en salud vinculados al g&#xe9;nero y a la interseccionalidad, detectar vac&#xed;os de conocimiento y brindar recomendaciones.</AbstractText><AbstractText Label="M&#xc9;TODOS" NlmCategory="UNASSIGNED">revisi&#xf3;n de alcance global, con la detecci&#xf3;n de vac&#xed;os de conocimiento y recomendaciones. Se busc&#xf3; en ocho bases de datos: MEDLINE (Pubmed), Anthropological Index Online, Studies on Women &amp; Gender Abstracts, LILACS, Scielo, Global Index Medicus, Web of Science, Google acad&#xe9;mico y se hizo una b&#xfa;squeda manual en Google de documentos de los &#xfa;ltimos 10 a&#xf1;os, sin restricciones de idioma y geogr&#xe1;ficas. Se realiz&#xf3; un an&#xe1;lisis de contenido de los estudios incluidos.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="UNASSIGNED">855 registros fueron identificados y 21 cumplieron con los criterios de inclusi&#xf3;n. Predominan los estudios que tuvieron como primer autor/a una mujer (13/21), aunque en la autor&#xed;a global se destacaron los hombres (10/21). El modelo binario fue el enfoque principal (16/21). La mayor&#xed;a (18/21) se publicaron a partir del 2020. Se abordaron principalmente temas relacionados con la COVID-19 y la salud sexual y reproductiva (antes de la pandemia), y en menor medida la salud mental. Se identificaron interacciones entre diferencias de sexo/g&#xe9;nero en la desinformaci&#xf3;n/infodemia en salud especialmente en mujeres, colectivos de g&#xe9;nero diverso, personas mayores y poblaci&#xf3;n de bajo nivel socioeducativo.</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="UNASSIGNED">existen brechas de conocimiento en el tema explorado, con escaso n&#xfa;mero de estudios, y limitaciones de alcances y del enfoque de g&#xe9;nero y/o feminista (m&#xe1;s all&#xe1; del binario). No obstante, los resultados tentativos constatan la presencia de inequidades de g&#xe9;nero e interseccionalidad en la desinformaci&#xf3;n en salud.</AbstractText><AbstractText Label="PALABRAS CLAVE" NlmCategory="UNASSIGNED">infodemia, desinformaci&#xf3;n, g&#xe9;nero, COVID-19, revisi&#xf3;n sistem&#xe1;tica.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moyano</LastName><ForeName>Daniela Luz</ForeName><Initials>DL</Initials><Identifier Source="ORCID">0000-0003-2728-9708</Identifier><AffiliationInfo><Affiliation>Departamento de Ciencias de la Salud, Universidad Nacional de La Matanza, San Justo, Buenos Aires, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Universitario de Estudios de G&#xe9;nero, Universidad Carlos III de Madrid, Getafe, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agull&#xf3;-Tom&#xe1;s</LastName><ForeName>Mar&#xed;a Silveria</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Instituto Universitario de Estudios de G&#xe9;nero, Universidad Carlos III de Madrid, Getafe, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de An&#xe1;lisis Social, Universidad Carlos III de Madrid, Getafe, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zorrilla-Mu&#xf1;oz</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Instituto Universitario de Estudios de G&#xe9;nero, Universidad Carlos III de Madrid, Getafe, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Bioingenier&#xed;a, Universidad Miguel Hern&#xe1;ndez de Elche, Comunidad Valenciana, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Glob Health Promot</MedlineTA><NlmUniqueID>101497462</NlmUniqueID><ISSNLinking>1757-9759</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaraci&#xf3;n de conflictos de inter&#xe9;sesNing&#xfa;n conflicto declarado.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>6</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>6</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>6</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38183208</ArticleId><ArticleId IdType="doi">10.1177/17579759231216945</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>